×
About 14,223 results

ALLMedicine™ Lung Adenocarcinoma Center

Research & Reviews  5,483 results

Integration of bioinformatics analysis and experimental validation identifies plasma ex...
https://doi.org/10.1002/cam4.4788
Cancer Medicine; Wu J, Feng Z et. al.

May 20th, 2022 - The aim of this study was to identify miRNAs in plasma exosomes as noninvasive biomarkers for the early diagnosis of lung adenocarcinoma (LUAD). First, exosomal miRNA profiling of three patients with early LUAD and three patients with benign lung ...

Lipid metabolism-related gene prognostic index (LMRGPI) reveals distinct prognosis and ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9108406
International Journal of Medical Sciences; Jiang A, Chen X et. al.

May 19th, 2022 - Background: Lipid metabolism plays a pivotal role in cancer progression and metastasis. This study aimed to investigate the prognostic value of lipid metabolism-related genes (LMRGs) in early-stage lung adenocarcinoma (LUAD) and develop a lipid me...

Small nucleolar RNA host gene 3 functions as a novel biomarker in liver cancer and othe...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9048787
World Journal of Gastroenterology; Shan DD, Zheng QX et. al.

May 19th, 2022 - Cancer has become the most life-threatening disease in the world. Mutations in and aberrant expression of genes encoding proteins and mutations in noncoding RNAs, especially long noncoding RNAs (lncRNAs), have significant effects in human cancers....

MDIG, a 2‑oxoglutarate‑dependent oxygenase, acts as an oncogene and predicts the progno...
https://doi.org/10.3892/ijo.2022.5372
International Journal of Oncology; Geng F, Yang W et. al.

May 19th, 2022 - Recent studies have indicated that mineral dust‑induced gene (MDIG) is an oncogene induced by environmental factors, which has a key role in the development and progression of various tumor types, through epigenetic modifications; however, there a...

Deconvolution of malignant pleural effusions immune landscape unravels a novel macropha...
https://doi.org/10.1136/jitc-2021-004239
Journal for Immunotherapy of Cancer; Bruschini S, Pallocca M et. al.

May 19th, 2022 - Immune checkpoint inhibitors are still unable to provide clinical benefit to the large majority of non-small cell lung cancer (NSCLC) patients. A deeper characterization of the tumor immune microenvironment (TIME) is expected to shed light on the ...

see more →

Guidelines  1 results

Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatmen...
https://doi.org/10.1200/JCO.2017.76.7293
Journal of Clinical Oncology : Official Journal of the Am... Kalemkerian GP, Narula N et. al.

Feb 6th, 2018 - Purpose In response to advances in the field, the College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) recently updated their recommendations ...

see more →

Clinicaltrials.gov  57 results

Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib
https://clinicaltrials.gov/ct2/show/NCT02759835

May 13th, 2022 - Background: EGFR tyrosine kinase inhibitors (TKI) have significantly improved the response rate (RR) and survival in patients with tumors harboring EGFR-sensitizing mutations. An invariable consequence of treatment with EGFR-TKIs is the developmen...

SLND or Not in cT1 GGO Invasive Lung Adenocarcinoma
https://clinicaltrials.gov/ct2/show/NCT04527419

Apr 20th, 2022 - Patients will be evaluated for inclusion criteria and exclusion criteria, and then they will sign informal consent if desired. He/she will be randomly assigned to the intervention according to a prepared random tables. Patients in the systematical...

AO-176 in Multiple Solid Tumor Malignancies
https://clinicaltrials.gov/ct2/show/NCT03834948

Apr 15th, 2022 - This is a first-in-human, Phase 1/2 multicenter, open-label, dose escalation and expansion study of AO-176 in patients with solid tumors. Part A of this study will examine escalating repeat doses of AO-176 monotherapy in patients with select advan...

Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC:Prospective Study
https://clinicaltrials.gov/ct2/show/NCT04401059

Mar 11th, 2022 - About 9.2%-45.8% of Chinese patients with Non-small cell lung cancer were positive for EGFR gene mutation. Gefitinib, Erlotinib, Icotinib, Afatinib showed efficacy superior to that of chemotherapy in the treatment of EGFR mutation positive advance...

Evaluation of Correlations Between Radiologic Features and Pathologic Subtypes of GGO LUAD Via WMS
https://clinicaltrials.gov/ct2/show/NCT05252676

Feb 23rd, 2022 - The pathological lepidic growth pattern was believed to relate to the ground-glass component, whereas invasive adenocarcinoma patterns relate to the solid component. However, the solid components might be fibrosis rather tumor; and previous studie...

see more →

News  148 results

Lung Cancer Field Targets Immunotherapy, Acquired Resistance, and Genomic Testing
https://www.onclive.com/view/lung-cancer-field-targets-immunotherapy-acquired-resistance-and-genomic-testing

Mar 31st, 2022 - To build on the advances that have been made in lung cancer over the past several years, researchers have their sights set on improving the efficacy of immunotherapy with novel approaches, the ability to overcome acquired resistance to targeted th...

Efforts to Target NRG1 Unlock New Pathways for Treatment
https://www.onclive.com/view/efforts-to-target-nrg1-unlock-new-pathways-for-treatment

Mar 1st, 2022 - The advent and implementation of advanced sequencing technologies in clinical practice have aided in the identification of highly active oncogenic gene fusions. RNA sequencing has illuminated the presence of NRG1 fusions, which, though rare, play ...

Distinct Genomic Profile of Lung Cancer in Never Smokers Comes Into Focus
https://www.onclive.com/view/distinct-genomic-profile-of-lung-cancer-in-never-smokers-comes-into-focus

Feb 10th, 2022 - During the past 2 decades, the treatment of patients with lung cancer has undergone a paradigm shift, a transformation fueled by genome sequencing efforts that have revealed oncogenic driver mutations and fostered targeted drug development. Tobac...

Enhanced Grasp of Oncogenic Drivers Leads to Expanded Treatment Options in NSCLC
https://www.onclive.com/view/enhanced-grasp-of-oncogenic-drivers-leads-to-expanded-treatment-options-in-nsclc

Nov 9th, 2021 - An increased understanding of the biology of non–small cell lung cancer (NSCLC) has led to a significant increase in therapeutic options for patients, according to Lyudmila A. Bazhenova, MD, a medical oncologist and professor of medicine at the Mo...

ROS1 Alterations in Advanced NSCLC
https://www.onclive.com/view/ros1-alterations-in-advanced-nsclc

Oct 27th, 2021 - Mark A. Socinski, MD: ROS1 is interesting in that it shares significant homology with ALK. They're close to 70 to 80% homologous proteins, if you will. ROS1 was discovered in the mid-1980s. And to my knowledge, I don't know that we understand the ...

see more →